MyoKardia Reports Third Quarter 2019 Financial Results
“As we look across the milestones recently achieved and those just ahead, we see steady progress on our near- and long-term corporate objectives. We are forging a position of disease-area leadership in the improved care of hypertrophic cardiomyopathy, while applying all that we are learning from those efforts to tackle additional targeted populations with diseases caused by diastolic or systolic dysfunction,” said Tassos Gianakakos, MyoKardia’s Chief Executive Officer. “Before year-end, we will be reporting 48-week data from our PIONEER-OLE study in obstructive HCM, as well as data from our Phase 2 MAVERICK-HCM study in patients with non-obstructive hypertrophic cardiomyopathy. Our momentum will continue into next year, with additional data and program progress planned across our portfolio for the first half of 2020, including the topline readout from our pivotal Phase 3 EXPLORER-HCM trial of mavacamten in obstructive HCM and the advancement of MYK-491 into a targeted genetic cardiomyopathy population.”
Recent Clinical Program Highlights
Mavacamten for Obstructive Hypertrophic Cardiomyopathy
- Completed Enrollment of 251 Patients in the Phase 3 EXPLORER-HCM Trial: Enrollment in the pivotal Phase 3 EXPLORER-HCM registrational clinical study of mavacamten for the treatment of symptomatic, obstructive hypertrophic cardiomyopathy (HCM) completed in July of 2019.
MyoKardiaanticipates reporting topline data from the EXPLORER-HCM trial in the second quarter of 2020.
- Presented 36-week Data from PIONEER-OLE Study of Mavacamten: At the
European Society of Cardiology Congress2019, Dr. Andrew Wangof Duke Universitypresented 36-week data from the PIONEER open-label extension study of twelve patients with obstructive HCM. Mavacamten treatment has resulted in durable reductions in obstruction of the left ventricular outflow tract (LVOT) while maintaining left ventricular ejection fraction (LVEF) at or above normal levels. Sustained improvements in multiple biomarkers of cardiac stress and diastolic filling pressures were also observed.
Formed Partnershipwith the Cleveland Clinic for Septal Reduction Therapy (SRT) Study: MyoKardiaand the Cleveland Clinicwill begin a randomized, double-blind study of symptomatic, obstructive HCM patients referred for septal reduction therapy (SRT) starting in the first half of 2020. The study will be conducted at leading HCM centers that regularly perform surgical myectomy or alcohol septal ablation procedures, with support from the established referral networks at those centers.
MYK-491 for Dilated Cardiomyopathy
- Reported Positive Data from Phase 2a Study of MYK-491: An interim analysis of 26 patients with stable heart failure due to left ventricular systolic dysfunction in the ongoing Phase 2a clinical trial showed that MYK-491 demonstrated improvement in systolic function, including stroke volume increases of greater than 10 percent relative to baseline on a placebo-adjusted basis, without impacting diastolic function. Given the favorable safety profile observed to date, the Phase 2a study has been extended to evaluate higher exposures of MYK-491.
- Announced Plans to Advance MYK-491 into a Phase 2 Study in Genetic Dilated Cardiomyopathy (DCM) Population: MyoKardia plans to advance MYK-491 into a Phase 2 clinical trial in DCM patients with certain genetic mutations of the cardiac sarcomere in the first half of 2020. Genetic mutations of the sarcomere impair the ability of the heart muscle proteins to function effectively, leading to progressive worsening of function. Genetic abnormalities contributing to DCM are estimated to be present in about 30-40% of DCM patients, corresponding to an estimated prevalence of 250,000 to 500,000 people in the U.S.
MYK-224 for HCM
- Began Dosing Healthy Subjects in a Phase 1 Clinical Trial of MYK-224: The Phase 1 clinical trial of MYK-224 is intended to evaluate safety, tolerability and pharmacokinetics. Pharmacodynamic effects on cardiac function and dimensions will also be assessed. MYK-224 joins MyoKardia’s growing portfolio of therapeutic candidates targeting proteins of the heart muscle to address cardiovascular diseases of excessive contraction, inadequate contraction, or impaired relaxation. Topline results are expected in mid-2020.
Recent Corporate Highlights
- Launched 2nd Annual MyoSeeds™ Research Grant Program Funding Cycle: MyoKardia received more than 60 proposals for its MyoSeeds initiative to support original, independent research in the biology and underlying mechanisms of cardiomyopathies and precision treatment for heart disease. Through this program, MyoKardia will fund up to four awards, with a total investment of up to $1 million in funding over 2019-2020. Award recipients will be announced in the first quarter of 2020.
Third Quarter 2019 Financial Results
- Cash Position: Cash, cash equivalents and investments (short-term and long-term) as of September 30, 2019 were $480.4 million, compared to
$394.8 millionas of December 31, 2018. The change in MyoKardia’s cash position was primarily attributable to the net proceeds from our March 2019offering of $271.2 million, offset by our year-to-date losses of $217.4 million, which includes a $80.0 millionpayment to Sanofifor the purchase of mavacamten and MYK-224 royalty rights.
MyoKardiadid not record revenue from the Sanoficollaboration during the third quarter and nine months ended September 30, 2019. For the three and nine months ended September 30, 2018, collaboration and license revenue totaled $9.2 million and $21.2 million, respectively. MyoKardiafulfilled its research and development obligations under the collaboration agreement during the year ended December 31, 2018, and no further revenue will be recorded under the agreement.
- R&D Expenses: Research and development expenses were $47.4 million for the third quarter of 2019, up from $15.9 million for the same period in 2018. R&D expenses in the first nine months of 2019 were $101.3 million, up from $49.7 million for the same period in 2018. The increase in R&D expenses was primarily driven by clinical trial activity for mavacamten, MYK-491, and MYK-224, a decrease in
Sanofireimbursement credits, increases in contract research, chemistry and biology expenses related to discovery and pre-clinical programs, increases in contract manufacturing expenses, and increases in headcount and stock-based compensation expense.
- SG&A Expenses: Selling, general and administrative expenses were $17.7 million for the three months ended September 30, 2019, compared to $11.0 million for the same period in 2018. For the first nine months of 2019, SG&A expenses were $45.2 million compared to $27.2 million in the same period in 2018. The increase in SG&A expenses was primarily attributable to an increase in headcount, stock-based compensation expense, professional service and consulting expenses, and office and facilities-related expenses.
- Net Loss: Net loss for the third quarter of 2019 was $141.8 million (
$3.07per share), of which $80.0 million( $1.73per share) was related to the non-recurring repurchase from Sanofiof royalty rights to mavacamten and MYK-224, and $61.8 million( $1.34per share) was related to loss from operations, compared to a net loss of $15.8 million ($0.39 per share) for the third quarter of 2018. For the nine months ended September 30, 2019, net loss was $217.4 million ( $4.91per share), of which $80.0 million( $1.81per share) was related to the repurchase of royalty rights and $137.4 million( $3.10per share) was related to loss from operations, compared to $52.0 million ( $1.38 per share) during the same period of 2018.
Based on the company’s current balance of cash and investments, MyoKardia estimates having sufficient funds to execute on current operating plans into the second half of 2021.
In lieu of conducting a third quarter financial results call,
MyoKardia’s mission is to change the world for people with serious cardiovascular disease through bold and innovative science.
Statements we make in this press release may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are usually identified by the use of words such as "anticipates," "believes," "estimates," "expects," "intends," "may," "plans," "projects," "seeks," "should," "will," and variations of such words or similar expressions. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements, including statements regarding the clinical and therapeutic potential of mavacamten, MYK-491 and MYK-224, the availability of the 48-week data from PIONEER-OLE and data from EXPLORER-HCM, as well as from the Phase 2 MAVERICK-HCM study in patients with non-obstructive HCM, the Company’s expectation with respect to release of data from these studies, the Company’s ability to advance MYK-491 into a Phase 2 study in patients with genetic DCM and the commencement of a study of mavacamten in symptomatic, obstructive HCM patients referred for SRT, and the timing of these events and the availability of data from the Phase 1 study of MYK-224 in healthy subjects, as well as the Company’s projected cash runway, reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements ad will be affected by a variety of risks and factors that are beyond our control including, without limitation, risks associated with the development and regulation of our product candidates, as well as those set forth in our Quarterly Report on Form 10-Q for the quarter ended
Senior Director, Corporate Communications and Investor Relations
Stern Investor Relations, Inc.
Condensed Consolidated Balance Sheets
(In thousands, except share and per share amounts)
|Cash and cash equivalents||$||235,159||$||246,122|
|Prepaid expenses and other current assets||7,598||4,760|
|Total current assets||424,689||319,446|
|Property and equipment, net||7,148||5,138|
|Operating lease right-of-use assets||1,028||—|
|Restricted cash and other||2,404||2,521|
|Liabilities and stockholders’ equity|
|Prepayment from collaboration partner||—||12,973|
|Operating lease liabilities - current||1,050||—|
|Total current liabilities||44,085||36,677|
|Other long-term liabilities||2,159||9|
|Commitments and contingencies|
|Preferred stock, $0.0001 par value; 5,000,000 shares authorized; none issued and outstanding||—||—|
|Common stock, $0.0001 par value, 150,000,000 shares authorized at September 30, 2019 and December 31, 2018; 46,218,925 and 40,288,949 shares issued and outstanding at September 30, 2019 and December 31, 2018, respectively||5||4|
|Additional paid-in capital||871,894||573,183|
|Accumulated other comprehensive income (loss)||453||(67||)|
|Total stockholders’ equity||452,353||370,567|
|Total liabilities and stockholders’ equity||$||498,597||$||407,253|
Condensed Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except share and per share amounts)
|Three Months Ended
|Nine Months Ended
|Collaboration and license revenue||$||—||$||9,188||$||—||$||21,158|
|Repurchase of royalty rights||80,000||—||80,000||—|
|Research and development||47,372||15,910||101,270||49,746|
|Selling, general and administrative||17,746||10,957||45,153||27,182|
|Total operating expenses||145,118||26,867||226,423||76,928|
|Loss from operations||(145,118||)||(17,679||)||(226,423||)||(55,770||)|
|Interest and other income, net||3,332||1,890||8,775||3,748|
|Loss before income taxes||(141,786||)||(15,789||)||(217,648||)||(52,022||)|
|Income tax expense (benefit)||16||—||(202||)||—|
|Other comprehensive (loss) income, net of tax effect of $17, $0, $(202) and $0, respectively||(44||)||37||520||(30||)|
|Net loss per share, basic and diluted||$||(3.07||)||$||(0.39||)||$||(4.91||)||$||(1.38||)|
|Weighted average number of shares used to compute net loss per share, basic and diluted||46,133,068||40,116,644||44,255,657||37,765,631|
Source: MyoKardia, Inc.